Skip to main content
. Author manuscript; available in PMC: 2016 Dec 22.
Published in final edited form as: Vaccine. 2015 Nov 1;33(52):7506–7512. doi: 10.1016/j.vaccine.2015.09.110

Fig. 1.

Fig. 1

Effect of allele-specific efficacy on breakthrough infections. The malaria vaccine contains two variants (red and cyan) of a polymorphic antigen (A). When an individual is infected by five different parasites with five variants (cyan, red, dark blue, yellow and green) of the same proteins (B), malaria clinical episodes with homologous (red and cyan) and closely related variants (dark blue) are prevented (C). Heterologous variants (yellow and green) may increase within the individual and the whole population (D, E).